Magnesium Deficiency Results in Oxidation and Fragmentation of DNA, Down Regulation of Telomerase Activity, and Ceramide Release in Cardiovascular Tissues and Cells: Potential Relationship to Atherogenesis, Cardiovascular Diseases and Aging

Burton M. Altura
Nilank C. Shah
Touro College of Osteopathic Medicine (Middletown), nilank.shah@touro.edu
Gatha J. Shah
Jose Luis Perez-Albela
Bella T. Altura

Follow this and additional works at: https://touroscholar.touro.edu/shs_pubs

Part of the Cardiovascular Diseases Commons, and the Molecular, Genetic, and Biochemical Nutrition Commons

Recommended Citation
Altura, B. M., Shah, N. C., Shah, G. J., Pérez-Albela, J. L., & Altura, B. T. (2016). Magnesium deficiency results in oxidation and fragmentation of DNA, down regulation of telomerase activity, and ceramide release in cardiovascular tissues and cells: Potential relationship to atherogenesis, cardiovascular diseases and aging. International Journal of Diabetology & Vascular Disease Research, 4(1e), 1-5.

This Editorial is brought to you for free and open access by the School of Health Sciences at Touro Scholar. It has been accepted for inclusion in School of Health Sciences Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.
Magnesium Deficiency Results in Oxidation and Fragmentation of DNA, Down Regulation of Telomerase Activity, and Ceramide Release in Cardiovascular Tissues and Cells: Potential Relationship to Atherogenesis, Cardiovascular Diseases and Aging

Altura BM1,2,3,4,5*, Shah NC1,5, Gatha J. Shah1, Pérez-Abela JL6, Altura BT1,3,4,5

1 Department of Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
2 Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.
3 Center for Cardiovascular and Muscle Research, SUNY Downstate Medical Center, Brooklyn, NY, USA.
4 The School of Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, NY, USA.
5 Bio-Defense Systems, Inc, Rockville Centre, NY, USA.
6 Instituto Bien de Salud, Lima, Peru.

Keywords: Ceramide; Nuclear Factor kB; Proto-Oncogenes; Sphingolipids; Cytokines; p53.

Introduction

Aging is clearly agreed to be critical in the etiology of metabolic decline in most human subjects as they near their 65th birthday. A great many human subjects at 65 years of age demonstrate clear signs of metabolic and physiological decline, atherosclerosis in most major arteries, high blood pressure, high serum cholesterol levels, diverse cardiovascular diseases, and often type 2 diabetes mellitus, which contribute in major ways to congestive heart failure by their 75th-85th years. It must be pointed out, here, that atherosclerosis, ischemic heart disease (IHD), coronary vasospasm, hypertension, and sudden-cardiac death (SCD) [2, 5, 6, 8, 9, 14-18]. Both animal and human studies have shown an inverse relationship between dietary intake of Mg and atherosclerosis [5, 6, 8, 9, 19-21]. The myocardial level of Mg has consistently been observed to be lower in subjects dying from IHD and SCD in soft-water areas than those in hard-water areas [2, 4-6, 8, 19-21]. Mg plays essential roles in more than 500 enzymatic reactions in the body and is required for all energy-generating reactions and oxidative phosphorylation [22]. More than 45 years ago, two of us demonstrated that Mg2+ behaves as a natural calcium channel blocker in both cardiac and vascular smooth muscle (VSM) cells [2, 23-26]. We also showed in experimental animals that Mg behaves as a natural statin in that it can lower blood cholesterol and triglyceride levels as well as act as a powerful vasodilator in the microcirculation and cardiac muscle relaxant [4, 6-8, 19, 27-30]. Hypermagnesemic diets have been shown to ameliorate hypertension and atherogenesis [1-6, 8-10, 19-22, 32-34]. Using sensitive and newly designed specific Mg2+ ion-selective electrodes, our laboratories demonstrated that patients with hypertension,...
Magnesium deficiency results in oxidation and fragmentation of DNA, downregulation of telomerase activity, and ceramide release in cardiovascular tissues and cells: relationship to telomerases, ceramide, NF-kB and proto-oncogenes

It is well-known that the aging process is associated with elevations in blood/serum/tissue/cell levels of many of the same proinflammatory cytokines and chemokines found in MgD animals, e.g., IL-1, IL-2, IL-6, TNF-alpha, among others [for recent reviews, see [61]]. Reduced levels of telomerases are known to be associated with elevated levels of several cytokines (e.g., TNF-alpha) in a number of aged cell types as well as in serum and cardiovascular tissues and VSM cells of MgD animals [for recent review, see [61]]; these phenomena being associated with (and correlated to ionized Mg levels; ceramide generation; and activation of NF-kB and proto-oncogene pathways] [61, 67, 68, 74-76]. It should be pointed out, here, that normal amounts of telomerases in all cell types are required to promote efficient cell cycle kinetics and normal cell growth [77, 78]. MgD is well-known to promote disturbances in cell cycle kinetics [79-81] via reactive oxygen and nitrogen species, most likely acting to downregulate telomerases [61]. Several studies have demonstrated that MgD, both in situ and in vitro, cause formation of reactive oxygen (ROS) and nitrogen species (NOS) [5, 6, 8, 61, 63-69]. Interestingly, the increased levels of cellular ROS and NOS were found to be associated with oxidation of DNA and increased levels of the tumor suppressor gene, increased levels of p53 and ceramide, in cardiovascular tissues and cells of MgD animals [61, 67, 68, 74-76].

Magnesium deficiency causes oxidation of DNA and increased levels of ceramide and p53: possible relation to cellular mutations and epigenetics

Recently, our laboratories have shown in animals, subjected to 21 days of MgD, that telomerase levels are downregulated and coupled to fragmentation and oxidation of DNA and increased levels of the tumor suppressor gene, p53 [61, 74]. We believe such data supports the idea that MgD could lead to multiple mutations in the genomes of multiple cell types found in the initiation of atherosclerosis and congestive heart failure. Previous studies from our group [8, 61-64, 67, 68, 74-76, 82, 83], when viewed in the light of these findings, would lend additional support to the hypothesis that mutations and transformations of VSM cells, endothelial cells, and cardiac myocytes caused by MgD, fragmentation of DNA, and oxidation of DNA (all seen in atherogenesis, hypertension, strokes, and congestive heart failure) may play major roles in the aging process, thus leading to multiple cardiovascular changes, including inflammations of the vascular walls, high blood pressure (due to formed elemental changes, release of ceramides, release of cytokines, excess wall lipid deposition and peroxidation, etc), cardiac dysfunctions, and eventual cardiac failure.

Several years ago, we suggested that MgD, by itself, probably acts as a genotoxic agent [74, 76]. As is known, one of ceramide's major pathophysiological actions is its ability to induce cell differentiation and transformation [83-87]. Abnormal cell differentiation, transformation, and growth are pivotal events of atherosclerosis, hypertension, and cardiac failure. Hyperplasia and cardiovascular hypertrophy are common events in aging, atherosclerosis, hypertension, and cardiac failure. However, the precise mechanism(s) regulating alterations in tissue mass are not completely understood [11, 87]. The tumor suppressor protein p53, ceramide, and telomerases are now known to play key roles in cell transformation, apoptotic events, and the aging process [11, 61, 73, 77, 78]. Both ceramide and p53 can induce cell cycle arrest (and senescence), induce programmed cell death, and are associated with oxidation and fragmentation of DNA (i.e., genotoxic events) [84-86, 88-91]. MgD can produce all of these alterations in multiple cell types, including cardiac and VSM cell types [4-6, 8, 59-64, 67, 68, 74-76]. In view of all of these events noted in MgD animals and cells we would be remiss if some discussion regarding the potential role of epigenetics to magnesium deficiency's long-term effects on the aging process was not pointed out here. All organisms begin as a single cell, which divides through a process of stem cells creating a mass, via a series of carefully-designed changes in gene expression, which is required to form the tissues and cells of the fetal organism. The process of epigenetics orchestrates which genes have to be turned-on in each cell type, and then maintains the particular type of gene expression, or in other words, the particular cell's molecular identity via how DNA encodes the gene. Anything that produces modifications in the chromatin structure can affect a particular gene expression via transcription [92, 93]. Thus, if MgD-states are, indeed, genotoxic as we have suggested [74, 76], then the chromatin structure of one or more cell types (e.g., cardiac, endothelial, or vascular) could be modified and affect one or more genes and cell phenotype, as is found in atherogenesis. DNA methylation, histone modification, and microRNA alterations are known epigenetic pathways. We, thus, believe that prolonged MgD-states should be categorized as another epigenetic mechanism. But, how could all of these irreversible MgD-induced changes be avoided with ease?

Importance of Mg supplemented drinking water and beverages

Over the past two-plus decades, our laboratories have been investigating the utility of Mg-supplemented or naturally-occurring spring waters to avoid the pitfalls of dietary-induced MgD-states [4-6, 8, 19, 37, 47, 61-68, 74-76]. Our results, so far, bolster the idea that water intake (e.g., from tap waters, well waters, bottled waters, beverages using tap/well/spring waters, or desalinated waters) in humans should contain at least 25-40 mg/liter/day of Mg" [61, 68, 74-76]. A number of experiments done in our labs indicate that most, if not all the cardiovascular...
manifestations observed in experimental animals found to be MgD, can be avoided by supplementing drinking waters with appropriate amounts of Mg²⁺. The latter inclusion in our diets should go a long way towards the prevention of cardiovascular diseases and ameliorate the aging process of bodily tissues and cells in humans worldwide. Interestingly, on the basis of our work, the World Health Organization has taken our recommendations seriously, for the first time [94].

Conclusions

There is a growing awareness that dietary deficiency of magnesium is becoming a serious problem, particularly in the Western World. Disturbances in diet are known to promote lipid deposition in the arterial walls and accelerate growth and transformation of smooth muscle cells in vascular walls which are linked to dietary deficiency of magnesium. The myocardial level of Mg has consistently been observed to be lowered in humans dying from IHD and sudden-cardiac death in soft-water areas than in those people living in hard-water areas. Use of specific Mg²⁺-selective electrodes has been useful, clinically, to reveal serious underlying Mg-deficient states in patients presenting with various cardiovascular diseases (CVD). Mg deficiency (MgD) is associated with pathophysiological and biochemical alterations characteristic of aging cells and tissues which are related to upregulation of enzymes in the sphingolipid pathway and release of cytokines, ROS, NOS, activation of NF-kB and proto-oncogenes, resulting in cellular production of free ceramide, p53, and disturbances in cell cycle kinetics of vascular smooth muscle and cardiac muscle cells. The consequences of MgD lead to oxidation and fragmentation of DNA and inflammation in cells of the cardiovascular system, phenomena characteristic of atherosclerosis, aging, and CVD. We suggest that MgD states are genotoxic and, thus, one or more cell types (e.g., cardiomyocytes, endothelial and/or vascular) could be modified and affect one or more genes and cell phenotype, as is found in atherogenesis, representing epigenetic cell-induced changes. Supplementation of drinking waters (including beverages) is recommended in order to prevent and reduce CVD.

Acknowledgments

The authors acknowledge that many of our experiments, over almost five decades were supported, in part, by Research Grants from the N.I.H. to BMA and BTA. These included grants from The National Heart, Lung, and Blood Institute; The National Institute on Drug Abuse; The National Institute on Alcoholism and Alcohol Abuse; and The National Institute on Mental Health.

References

[1]. Seelig MS (1980) Magnesium Deficiency in the Pathogenesis of Disease. Springer US, New York.

[2]. Altura BM, Altura BT (1985) New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Clinical aspects. Magnesium 4(5-6): 226-244.

[3]. Altura BM, Altura BT (1985) New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. II. Experimental aspects. Magnesium 4(5-6): 245-271.

[4]. Altura BM, Altura BT (1990) Magnesium and the cardiovascular system: Experimental and clinical aspects updated. Metals in Biological Systems 26: 359-416.

[5]. Altura BM, Altura BT (1995) Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherosclerosis. Cell Mol Biol Res 41(5): 347-359.

[6]. Altura BM, Altura BT (1995) Magnesium in cardiovascular biology. Sci. Am. Sci Med 2: 28-37.

[7]. Smetana R (1997) Advances in Magnesium Research. John Libbey, London.

[8]. Altura BM, Altura BT (2007) Magnesium: forgotten mineral in cardiovascular biology and angiogenesis. In New Perspectives in Magnesium Research. Springer, New York, 239-260.

[9]. Seelig MS, Rosanoff A (2003) The Magnesium Factor. The Penguin Group, New York.

[10]. Dean C (2014) The Magnesium Miracle. (3rd edn), Ballantine Books, New York.

[11]. Kumar V, Abbas AK, Aster JC (2015) Robbins and Cotran Pathologic Basis of Disease (9th edn). Elsevier Saunders, Philadelphia.

[12]. Ford ES, Mokdad AH (2003) Dietary magnesium intake in a national sample of US adults. J Nutr 133(9): 2879-2882.

[13]. Mosfegh A, Goldman J, Abuja J, Rhodes D, La Comba R (2009) What We Eat in America, NHANES 2005-2006: usual Macronutrient Intakes from Food and Water Compared to 1977 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus, and Magnesium. U.S. Department of Agricultural Research.

[14]. Marier JR, Neutra LC (1985) Quantifying the role of magnesium in the interrelationship between human mortality/morbidity and water hardness. Magnesium 42(3): 53-59.

[15]. Leary WP (1986) Content of magnesium in drinking water and deaths from ischaemic heart disease in white South Africans. Magnesium 5(3-4): 150-153.

[16]. Chipperfield B, Chipperfield JR (1979) Relation of myocardial metal concentration to water hardness and death-rates from ischaemic heart disease. Lancet (2(8145)): 709-712.

[17]. Marx A, Neutra RR (1997) Magnesium in drinking water and ischemic heart disease. Epidemiol Rev 19(2): 258-272.

[18]. Rubenowitz E, Molin I, Axelsson G, Rylander R (2000) Magnesium in drinking water in relation to morbidity and mortality from acute myocardial infarction. Epidemiology 11(4): 416-421.

[19]. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, et al. (1990) Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 87(5): 1840-1844.

[20]. Ouchi Y, Tabata RE, Stegipoulos K, Sato K, Hatori A, et al. (1999) Effect of dietary magnesium on development of atherosclerosis in cholesterolfed rabbits. Arterioscler Thromb 19(5): 732-737.

[21]. King JL, Miller RJ, Blue JP Jr, O’Brien WD Jr, Erdman JW Jr (2009) Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits. Nutr Res 29(5): 343-349.

[22]. de Baaij JHF, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. Physiol Rev 95(1): 1-46.

[23]. Altura BM, Altura BT (1981) Influence of magnesium on drug-induced contractions and ion content in rabbit aorta. Am J Physiol 220: 938-944.

[24]. Altura BM, Altura BT (1974) Magnesium and contraction of arterial smooth muscle. Microvasc Res 7(2): 145-155.

[25]. Altura BM, Altura BT (1981) Role of magnesium ions in contractility of blood vessels and skeletal muscles. Magnesium Bulletin 3(1a): 102-114.

[26]. Altura BM, Altura BT (1981) General anesthetics and magnesium ions as calcium antagonists. In: New Perspectives in Magnesium Antagonists. Am Physiol Soc 131-145.

[27]. Altura BM, Altura BT (1978) Magnesium and vascular tone and reactivity. Blood Vessels 15: 5-16.

[28]. Friedman HS, Nguyen TN, Mokraoui AM, Barbour RL, Murakawa T, et al. (1987) Effects of magnesium chloride on cardiovascular hemodynamics in the neutrally intact dog. J Pharmacol Exp Ther 243(1): 126-130.

[29]. Nagai I, Gebrewole A, Altura BT, Altura BM (1988) Magnesium salts exert direct vasodilator effects on rat cremaster muscle microcirculation. Arch Int Pharmacodyn Ther 294: 194-214.

[30]. Nishio A, Gebrewole A, Altura BT, Altura BM (1988) Comparative effects of magnesium salts on reactivity of arterioles and venules to constrictor agents. Am in situ study on microcirculation. J Pharmacol Exp Ther 246(3): 859-865.

[31]. Nishio A, Gebrewole A, Altura BT, Altura BM (1989) Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules. Arch Int Pharmacodyn Ther 298: 139-163.

[32]. Lutzhower C, Rayssiguier Y, Gueux E, Berthelot A (1988) Effect of moderate dietary magnesium deficiency on serum lipids, blood pressure and cardiovascular reactivity in normotensive rats. Br J Nutr 59(2): 243-250.

[33]. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A (2000) Effects of magnesium on reactivity of arterioles and venules to constrictor agents. An in situ study on microcirculation. J Pharmacol Exp Ther 243(1): 126-130.

[34]. Smetana R (1997) Advances in Magnesium Research. John Libbey, London.
Magnesium Deficiency Results in Oxidation and Fragmentation of DNA, Down regulation of Telomerase Activity, and Ceramide Release in Cardiovascular Tissues and Cells: Potential Relationship to Atherogenesis, Cardiovascular Diseases and Aging.

Altura BM, Altura BT (1996) Role of magnesium in pathophysiological processes and the clinical utility of magnesium ion-selective electrodes. Scand J Clin Lab Invest 56(Suppl 224): 211-234.

Altura BM, Gebrewold A, Altura BT, Brautbar N (1996) Magnesium deficiency impairs myocardial carbohydrate and lipid metabolism and cardiac bioenergetics and raises myocardial calcium content in vivo: relationship to etiology of cardiac diseases. Biochem Mol Biol Int 40(6): 1183-1190.

Altura BM, Gebrewold A, Zhang A, Altura BT (2003) Low extracellular magnesium ions induce lipid peroxidation and activation of nuclear factor-kB in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes. Neurosci Lett 341(1): 189-192.

Dickens BF, Weglicki WB, Li YS, Mak IT (1992) Magnesium deficiency in vivo enhances free radical-induced intracellular oxidation and cytotoxicity of endothelial cells. FASEB J 6(13): 187-191.

Dickens BF, Mak IT, Kramer JH, Dickens BT, Cassidy MM, et al. (1996) Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res 31(5): 677-682.

Altura BM, Kostellow AB, Zhang A, Li W, Morrall GA, et al. (2003) Expression of the nuclear factor-kB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypotension, atherogenesis, and stroke. Am J Hypertens 16(9 Pt 1): 701-707.

Altura BM, Shah NC, Jiang XC, Li Z, Perez-Albella JL, et al. (2009) Short-term magnesium deficiency results in decreased levels of serum sphingomyelin, lipid peroxidation, and apoptosis in cardiovascular tissues. Am J Physiol Heart Circ Physiol 297(1): H86-H92.

Altura BM, Shah NC, Shah GJ, Perez-Albella JL, et al. (2010) Magnesium-deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells: relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review. Int J Clin Exp Med 7(1): 1-21.

Neves D (2015) Anti-Aging Nutrients. Evidence-based Prevention of Age-Associated Diseases. Wiley Blackwell, Oxford.

Altura BM, Shah NC, Li Z, Jiang X, Zhang A, et al. (2010) Short-term magnesium deficiency upregulates sphingomyelin synthase and p53 in cardiovascular tissues: a complication of clinical magnesium deficiency due to de novo synthesis of ceramide. Am J Physiol Heart Circ Physiol 299(4): H2064-H2055.

Altura BM, Shah NC, Shah GJ, Zhang A, Li W, et al. (2014) Short-term Mg-deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells: possible link to NF-kB, cokytines, ceramide salvage sphingolipid pathway and PKC-zeta: a hypothesis and review. Int J Clin Exp Med 7(1): 1-21.

Walker GM (1986) Magnesium and cell cycle control: an update. Magnesium 5(1): 9-33.

Norton WS (1988) The role of magnesium in nucleic acid and protein metabolism. Magnesium 7(6-7): 234-248.

Altura BM, Shah NC, Shah GJ, Perez-Albella JL, et al. (2016) Insights into the possible mechanisms by which platelet-activating factor and PAF-receptor functions in vascular smooth muscle in magnesium deficiency and vascular remodeling: possible links to atherogenesis, hypertension and cardiac
failure. Int J Cardiol Res 3(1e): 1-3.

[83]. Haimovitz-Friedman A, Kolesnick RN, Fuks Z (1997) Ceramide signaling in apoptosis. Br Med Bull 53(3): 539-553.

[84]. Hannun YA, Obeid LM (2002) The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277(29): 25847-25850.

[85]. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T (2001) Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 31(6): 717-728.

[86]. Auge N, Negre-Salvayre A, Salvayre R, Levade T (2000) Sphingomyelin metabolites in vascular signaling and atherosclerosis. Prog Lipid Res 39(3): 207-239.

[87]. Intengan HD, Schiffrin EL (2001) Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38(3 Pt 2): 581-587.

[88]. Andreassi M (2003) Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat Res 543(1): 67-86.

[89]. Mercer J, Mahmoudi M, Bennett M (2007) DNA damage, p53, apoptosis and vascular disease. Mutat Res 621(1-2): 75-86.

[90]. Meek DW (2009) Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.

[91]. Vousten KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9(10): 691-700.

[92]. Katada S, Imhof A, Sassone-Corsi P (2012) Connecting threads: Epigenetics and metabolism. Cell 148(1-2): 24-28.

[93]. Lu C, Thompson CB (2012) Metabolic regulation of epigenetics. Cell Metab 16(1): 9-17.

[94]. World Health Organization (2009) Calcium and Magnesium in Drinking Water. WHO Publications, Geneva.